Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness.

Zezos, Petros; Kabakchiev, Boyko; Weizman, Adam V; Nguyen, Geoffrey C; Narula, Neeraj; Croitoru, Kenneth; Steinhart, A Hillary; Silverberg, Mark S

Zezos, Petros; Kabakchiev, Boyko; Weizman, Adam V; Nguyen, Geoffrey C; Narula, Neeraj; Croitoru, Kenneth; Steinhart, A Hillary; Silverberg, Mark S.

Afiliação

Zezos P; Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
Kabakchiev B; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Canada.
Weizman AV; Lunenfeld-Tannenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
Nguyen GC; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Canada.
Narula N; Lunenfeld-Tannenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
Croitoru K; Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
Steinhart AH; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Canada.
Silverberg MS; Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.

J Can Assoc Gastroenterol ; 3(2): 74-82, 2020 Apr.

Article em En | MEDLINE | ID: mdl-32328546

Palavras-chave

Crohn's disease; mucosal healing; remission; steroid-free; ulcerative colitis; vedolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Can Assoc Gastroenterol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google